Comparing Hodgkin lymphoma regimens: ABVD, N-AVD, BV-AVD, and BrECADD

The first rule when comparing Hodgkin lymphoma treatments is to check that the recommendations concern the same setting. Early favorable disease, untreated advanced disease, relapse before transplantation, and nodular lymphocyte-predominant disease should not be placed in one “best treatment” ranking. Studies can report impressive response rates while enrolling different patients and using different later treatment. Those percentages cannot simply be compared as if they came from one trial.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The table is not an order of preference. Regional guidelines, authorizations, and local capacity can affect the choices. A recommendation should identify the conditions the patient meets, rather than merely labeling a regimen “advanced” or “traditional.” [S2][S23]
Chemotherapy with local radiation and chemotherapy alone involve different balances of disease control and normal-tissue exposure. If omitting radiation requires more chemotherapy, drug-related risk may change. If radiation permits a shorter chemotherapy program, the organs and doses exposed need explanation. Both strategies should be described completely rather than presenting only the disadvantages of one. [S16][S17]
Ask each center to record the recommended program and supporting evidence, treatment phases, adjustment points, principal personal risks, urgent-care arrangements, and budget assumptions. If recommendations differ, identify whether the disagreement concerns diagnosis, risk definitions, interpretation of evidence, or practical access. A further consultation can then address a specific unresolved issue.

Quick answer

Full guide

This guide focuses on common initial-treatment discussions for classical Hodgkin lymphoma. It can help organize a second opinion, but does not provide a menu for assembling a new regimen. Drug combinations, administration, supportive care, and response assessment form a complete program. Replacing or removing one component can change the evidence supporting it.

Put each candidate in its proper context

Program	Typical discussion	Details needed for a fair comparison
ABVD with an appropriate PET-adapted approach	Selected early and advanced classical disease pathways	Bleomycin exposure, radiation plans, and PET rules
Nivolumab-AVD	Untreated advanced classical disease	Immune history, age criteria, and local indication
Brentuximab vedotin-AVD	An option for untreated advanced disease	Neuropathy, blood-count support, and access
PET-guided BrECADD	Patients matching the relevant intensive-treatment evidence	Fitness, supportive resources, PET timing, and fertility
Chemotherapy plus involved-site radiation	Selected early classical disease	Original sites, organ exposure, and relapse tradeoffs
A selected radiation-omission pathway	Patients meeting a defined program's criteria	Chemotherapy exposure and the exact response threshold

The table is not an order of preference. Regional guidelines, authorizations, and local capacity can affect the choices. A recommendation should identify the conditions the patient meets, rather than merely labeling a regimen “advanced” or “traditional.” [S2][S23]

ABVD: substantial experience with specific lung concerns

ABVD has extensive clinical experience and remains reasonable in appropriate settings. Establish whether radiation is planned, whether PET will adapt later treatment, and which drugs continue afterward. It is not one identical schedule used in every stage. [S1]

Bleomycin can cause pulmonary toxicity, making lung history and other personal factors relevant. RATHL supports omitting later bleomycin in selected advanced-disease patients with an appropriate early PET response. That does not mean every early-stage patient can remove it from the first dose, or that all respiratory monitoring becomes unnecessary. [S5]

If ABVD is recommended, ask whether the reasons include your disease category, long-term evidence, health, or ability to sustain the full course. A lower price or longer history does not independently prove inferior care. Equally, familiarity with a regimen is not a reason to avoid discussing a newer option's potential benefit.

Nivolumab-AVD and brentuximab vedotin-AVD

S1826 directly randomized patients with untreated advanced classical disease between these two complete combinations. Its findings support better disease control with nivolumab-AVD in the population studied and describe differences in adverse-event burden. It does not resolve treatment for every early-stage patient, every comorbidity, or every previously treated setting. [S4]

The checkpoint component in nivolumab-AVD brings immune-related considerations involving the lungs, bowel, liver, and endocrine organs. Autoimmune disease and transplant history need particular assessment. Brentuximab vedotin can cause neuropathy, so existing numbness, gait problems, or difficulty with fine movements matters. Labels such as “immunotherapy” and “targeted treatment” do not establish that one is universally gentler. [S7]

Compare each program's blood-count support, laboratory schedule, symptom reporting, and possible admission needs. A quotation that includes the medicine but omits necessary supportive care is not equivalent to a complete-course estimate. Suitability includes both anticancer activity and the capacity to finish treatment safely.

BrECADD and escalated BEACOPP

HD21 compared PET-guided BrECADD with escalated BEACOPP in a defined advanced-disease population. BrECADD includes brentuximab vedotin and several chemotherapy drugs; it is not another spelling of brentuximab vedotin-AVD. If proposed, the clinician should explain how fitness, monitoring, support, and PET adaptation fit that program. [S6]

HD21 and S1826 used different comparators and designs. Selecting the best numbers from the two publications cannot establish a direct winner between BrECADD and nivolumab-AVD. Where there is no head-to-head comparison under matching conditions, the team is choosing from available evidence and individual factors, with uncertainty that should be stated rather than concealed.

The fertility analysis of HD21 adds information about gonadal recovery, but hormonal recovery, natural conception, and becoming a parent are distinct outcomes. A comparatively improved fertility profile does not eliminate the need to discuss preservation before treatment. [S27][S10][S11]

Radiation decisions compare entire strategies

Chemotherapy with local radiation and chemotherapy alone involve different balances of disease control and normal-tissue exposure. If omitting radiation requires more chemotherapy, drug-related risk may change. If radiation permits a shorter chemotherapy program, the organs and doses exposed need explanation. Both strategies should be described completely rather than presenting only the disadvantages of one. [S16][S17]

HD17 supports omission within a particular early unfavorable pathway when its response conditions are met. HD16 and related early favorable evidence show that some omission strategies increase relapse. These observations are not interchangeable because the populations and chemotherapy differ. Apply the patient's exact risk definition and treatment to the evidence rather than adopting “negative PET means no radiation” as a universal rule. [S24][S25]

If proton or alternative photon techniques are discussed, request comparison of actual plans for relevant heart, lung, breast, or other organ exposure. A technology name is a means of delivering treatment. The meaningful question is whether it improves the patient's plan enough to justify additional cost or travel.

Personal factors change what matters most

Personal issue	Priority question
Lung disease or persistent respiratory symptoms	How will drug toxicity, infection, and the existing disease be distinguished?
Numbness or work requiring precise hand function	What neurologic changes trigger reassessment or adjustment?
Autoimmune disease or chronic immunosuppression	What specialist input is needed before PD-1 treatment?
Future parenting plans	What preservation time and options are available?
Long travel distance or cross-border care	Can infusions, monitoring, and urgent support be delivered continuously?

These are prompts for assessment, not an absolute contraindication list for patients to apply themselves. The same degree of numbness can have different practical consequences for a person operating tools and someone whose work is less dependent on hand sensation. The clinician needs to understand that difference.

Other priorities also deserve mention: looking after children, limited paid leave, or difficulty obtaining transport may affect how a regimen is supported. They should lead to practical solutions or a discussion among medically reasonable options, not an unplanned patient-led reduction in treatment.

Read the meaning of “better” carefully

Complete response, progression-free survival, and overall survival measure different things. A high early response rate does not establish that no further treatment will ever be needed. Improved progression-free survival cannot automatically be converted into a specific number of extra years for an individual. Consider follow-up time, comparator, treatment discontinuation, and severe toxicity alongside the headline result. [S4][S6]

Newer combinations may still need longer observation for cardiovascular, reproductive, or second-cancer effects. Older programs have longer follow-up, but some historical patients received older supportive care or larger radiation fields. Neither incomplete long-term data nor historical exposure should be presented as a precise prediction for today's patient.

When a claim comes from an indirect comparison, subgroup, or single-arm study, ask the clinician how much confidence it adds beyond the randomized evidence. This does not make the research useless; it clarifies which conclusions are firm and which are being inferred.

Verify Chinese access and costs separately

The FDA's March 2026 first-line nivolumab-AVD approval is US regulatory information. China's official 2025 guidance distinguishes drug-specific treatment settings and separately marked foreign indications. Later local label updates, hospital supply, and payment support require current confirmation. A paper showing benefit does not by itself establish that a particular patient can obtain the same program in China. [S3][S7]

Use renminbi throughout quotation comparisons and standardize formulations, anticipated cycles, support medicines, PET examinations, radiation, and admission assumptions. Ask which items are included, which may be charged separately, and how a medically necessary change produces a revised estimate. Two totals with different scopes do not establish which hospital is less expensive. [S12]

International patients should also account for accommodation, an accompanying person, interpretation, records, and monitoring after returning home. A regimen may be deliverable in China while continuation medicines or immune-toxicity care are difficult to obtain at home. That affects the suitability of the full pathway and should be discussed before committing to travel.

Compare two recommendations on one page

Ask each center to record the recommended program and supporting evidence, treatment phases, adjustment points, principal personal risks, urgent-care arrangements, and budget assumptions. If recommendations differ, identify whether the disagreement concerns diagnosis, risk definitions, interpretation of evidence, or practical access. A further consultation can then address a specific unresolved issue.

After making a choice, retain the discussion record. A new research headline is not automatically a reason to switch a course that has already started. The team must assess whether the evidence applies to your current response and toxicity. The purpose of comparison is an understandable, deliverable plan that can be adjusted for valid medical reasons, rather than a continuing obligation to chase every new regimen name.